Conrad-Marr Drug (McAlister Drug Corporation), Yukon, OK

Is Conrad-Marr Drug (McAlister Drug Corporation) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Conrad-Marr Drug (McAlister Drug Corporation) hold a Oklahoma pharmacy license?

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

Has Conrad-Marr Drug (McAlister Drug Corporation) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Aug 21, 2020), 1 state referral letter (Oct 2, 2020) and 1 FMD-145 letter (Oct 1, 2020) for Conrad-Marr Drug (McAlister Drug Corporation). State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
McAlister Drug Corporation; Conrad-Marr Drug
Location
Yukon, OK
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Oct 2, 2020
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as McAlister Drug Corporation, (dba Conrad-Marr Drug), a 503A facility, with 4 dated actions.

Document
Oct 2, 2020State referral letterReferral Letter to the Oklahoma State Board of Pharmacy Issued 10/2/2020FDA copy (archived)
Oct 1, 2020FMD-145 letterFMD-145 Letter Issued 10/01/2020Not linked by FDA
Aug 21, 2020Untitled letterUntitled Letter Issued 08/21/2020fda.gov
Oct 3, 2019Form 483483 Issued 10/03/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists MCALISTER DRUG CORPORATION, Yukon, OK (FEI number 3012906298), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 3, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30129062981103538

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 23, 2019 to Oct 3, 2019: 6 observations

Firm on the cover
MCALISTER DRUG CORPORATION, 948 S Yukon Pkwy, Yukon, OK 73099-4589
FEI number
3012906298
Establishment type on the cover
Producer of Non-Sterile Drug Products
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm is using non-pharmaceutical grade materials to make drug products. For example,

a) Your firm uses <Redacted B4> in certain drug products whose formulation require <Redacted B4> Your firm is also using the <Redacted B4> to make <Redacted B4> for use in certain drug products. Your firm does not perform testing (analytical or microbiological} to show the <Redacted B4> at least/at minimum meets the specifications for <Redacted B4> Examples of lots made using the <Redacted B4> made from <Redacted B4> include:

i.

LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19.

ii. LIDO 20%/TETR 4%/PHENYL 2% made on 4/17/19, 4/30/19, 6/11/19, 6/26/19 and 8/12/19. Examples of products made using the <Redacted B4> Include:

V. <Redacted B4> used to <Redacted B4> for the LIDO 20%/TETR 4%/PHENYL 2% made on 4/17/19, 4/30/19, 6/11/19, 6/26/19 and 8/12/19 and the LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19.

b) Your firm uses[ <Redacted B4> for making drug products. The <Redacted B4> is labeled "FOR TECHNICAL USE ONLY". ...

Read the full 483 (PDF on fda.gov)

Observation 2

You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, your firm <Redacted B4> to clean work surfaces, utensils and equipment such as the <Redacted B4> used to make hazardous drug products. Your firm does not use a deactivating agent to ensure removal of residue in between batches of hazardous drugs to prevent cross contamination. Active pharmaceutical ingredients (API) used include testosterone, estradiol, 5-fluorouracil, DHEA, and progesterone.

Observation 3

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm does not have a written stability testing program to determine Beyond Use Dates (BUD)/expiration dates placed on all your drug products. For example,

a) Itch Relief Gel made on 4/11 /19, 6/24/19, 7/11 /19 and 9/13/19. This product is made with <Redacted B4> and is assigned an expiration date of 180 days.

b) LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19. This product is made with <Redacted B4> land is assigned an expiration date of 3 months.

c) LIDO 20%/TETR 4%/PHENYL 2% made on 4/17/19, 4/30/19, 6/11/19, 6/26/19 and 8/12/19. This product is made with <Redacted B4> and is assigned an expiration date of 180 days.

Observation 4

Specifically, your firm does not conduct routine testing for potency for all drug products produced by your firm. Examples include the following,

a) Itch Relief Gel made on 4/11/19, 6/24/19, 7/11 /19 and 9/13/19.

b) LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19.

c) LIDO 20%/TETR 4%/PHENYL 2% made on 4/17/19, 4/30/19, 6/11 /19, 6/26/19 and 8/12/19.

Observation 5

Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, your firm does not perform external calibration of the analytical balances used to weigh ingredients, including active pharmaceutical ingredients (API), used to make drug products. Examples of lots made include the following:

i.

PROMETH (A) 12.5MG/0.1 ML PLOGEL made on 2/25/19.

ii. Itch Relief Gel made on 4/11 /19, 6/24/19, 7/11 /19 and 9/13/19.

iii. LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19.

Observation 6

Specifically,

a) LIDO 12.5%/TETR 12.5%/PRILO 3%/PHENYL 3% DENT made on 9/19/19. Your firm did not document on the formulation sheet, the lot of <Redacted B4> used. Your firm also did not document if the <Redacted B4> and the preparation of a <Redacted B4> solution, including the lot of <Redacted B4> used.

b) LIDO 20%/TETR 4%/PHENYL 2% made on 4/17/19, 4/30/19, 6/11 /19, 6/26/19 and 8/12/19. Your firm did not document on the formulation sheet, the lot of <Redacted B4> used. Your firm also did not document if the, <Redacted B4> and the preparation of a <Redacted B4> solution, including the lot of <Redacted B4> used.

State board of pharmacy records

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.